Understanding how cancer drugs affect transcriptional hubs in multiple myeloma
Official title: Project 2: Investigating regulation of transcriptional condensates in multiple myeloma
Funded at Dana-Farber Cancer Inst · NIH-11403922 · Data updated 2026-11-12
A research team is studying how cancer cells in multiple myeloma regulate gene activity and how drugs interact with those gene-control hubs to possibly improve treatments.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | December 1, 2011 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $291,983 |
| NIH project number | 5P01CA155258-14 |
| Project ID | NIH-11403922 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with multiple myeloma or related blood cancers may benefit from future therapies informed by this research.
✕Less likely to help
People without cancer or with cancer types not driven by transcriptional condensates may not directly benefit.
What this research studies
This project explores how transcriptional condensates—tiny, molecule-packed regions that control gene activity—shape the behavior of multiple myeloma cells. It looks at how super-enhancers and transcription factors come together to drive cancer genes, and how newly made RNA influences these hubs. The researchers are also examining how anticancer drugs accumulate in these condensates and how that changes drug effectiveness near their targets. The findings could guide the design of better therapies that disrupt harmful gene regulation in myeloma. The work builds on prior studies and uses advanced molecular and biochemical approaches to map these processes.
Why it matters
Potential benefit: This work could lead to new strategies that make anticancer drugs work more effectively against multiple myeloma.
How similar studies have gone: Prior studies in this area have shown that targeting transcriptional regulation can influence cancer growth, with ongoing exploration of condensate biology being promising but still early.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Young, Richard — Dana-Farber Cancer Inst
- Study coordinator: Young, Richard
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.